CD44 and nasopharyngeal carcinoma: For pharmacological intervention, Mdivi-1 is the most common and generally recognized DRP1-selective inhibitor that has been reported to reduce the percentage of SP+ or CD44+ CSC subpopulations, the expression of stemness genes, and the formation capacity of tumorspheres in vitro and in tumors in vivo in the context of nasopharyngeal carcinoma (NPC), liver cancer, ovarian cancer, etc. [86, 91, 120, 121] (Fig. 3B).